Johnson & Johnson
JNJNYSEHealthcare● Active
$232.77
+$4.60(+2.02%)
Market Cap$560.3B
P/E Ratio—
52W High$251.71
52W Low$149.04
Johnson & Johnson (JNJ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
JNJ · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 14, 2026EPS Actual
$2.70
Est. $2.68 · +0.8%
Revenue
$24.06B
Est. $23.61B · +1.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 14, 2026
After Market Close
▲ Beat Revenue🔥 11-Quarter EPS Beat Streak
JNJ reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 15, 2026 | $2.83 | — | — | — | $24.96B | — |
| — Q2 FY2026 | Apr 14, 2026 | $2.68 | $2.70 | +0.8% | $24.06B | $23.61B | +1.9% |
| — Q1 FY2026 | Jan 21, 2026 | $2.46 | $2.46 | +0.0% | $24.56B | $24.15B | +1.7% |
| ▲ Q4 FY2025 | Oct 14, 2025 | $2.76 | $2.80 | +1.4% | $23.99B | $23.76B | +1.0% |
| ▲ Q3 FY2025 | Jul 16, 2025 | $2.68 | $2.77 | +3.4% | $23.74B | $22.85B | +3.9% |
| ▲ Q2 FY2025 | Apr 15, 2025 | $2.58 | $2.77 | +7.4% | $21.89B | $21.56B | +1.6% |
| ▲ Q1 FY2025 | Jan 22, 2025 | $1.99 | $2.04 | +2.5% | $22.52B | $22.43B | +0.4% |
| ▲ Q4 FY2024 | Oct 15, 2024 | $2.21 | $2.42 | +9.5% | $22.47B | $22.17B | +1.4% |
Q3 FY2026
Jul 15, 2026
EPS Actual
—
EPS Est.
$2.83
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 14, 2026
EPS Actual
$2.70
EPS Est.
$2.68
EPS Surpr.
+0.8%
Revenue
$24.06B
Q1 FY2026
Jan 21, 2026
EPS Actual
$2.46
EPS Est.
$2.46
EPS Surpr.
+0.0%
Revenue
$24.56B
Q4 FY2025
Oct 14, 2025Beat
EPS Actual
$2.80
EPS Est.
$2.76
EPS Surpr.
+1.4%
Revenue
$23.99B
Q3 FY2025
Jul 16, 2025Beat
EPS Actual
$2.77
EPS Est.
$2.68
EPS Surpr.
+3.4%
Revenue
$23.74B
Q2 FY2025
Apr 15, 2025Beat
EPS Actual
$2.77
EPS Est.
$2.58
EPS Surpr.
+7.4%
Revenue
$21.89B
Q1 FY2025
Jan 22, 2025Beat
EPS Actual
$2.04
EPS Est.
$1.99
EPS Surpr.
+2.5%
Revenue
$22.52B
Q4 FY2024
Oct 15, 2024Beat
EPS Actual
$2.42
EPS Est.
$2.21
EPS Surpr.
+9.5%
Revenue
$22.47B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $4.15 | $4.22 | $4.29 | 6 |
| Q3 FY2028 | $3.39 | $3.44 | $3.51 | 6 |
| Q2 FY2028 | $3.25 | $3.30 | $3.36 | 6 |
| Q1 FY2028 | $3.00 | $3.04 | $3.10 | 6 |
| Q4 FY2027 | $3.28 | $3.33 | $3.39 | 5 |
| Q3 FY2027 | $3.17 | $3.21 | $3.27 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $31.8B | $32.1B | $32.6B | 4 |
| Q3 FY2028 | $28.1B | $28.4B | $28.8B | 8 |
| Q2 FY2028 | $27.5B | $27.8B | $28.2B | 5 |
| Q1 FY2028 | $25.9B | $26.2B | $26.6B | 4 |
| Q4 FY2027 | $28.4B | $28.8B | $29.2B | 5 |
| Q3 FY2027 | $26.7B | $27.0B | $27.3B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 14, 2026 | +0.8% | $237.96 | $240.10 | +0.90% |
| ▲ Q1 FY2026 | Jan 21, 2026 | +0.0% | $218.21 | $218.01 | -0.09% |
| ▲ Q4 FY2025 | Oct 14, 2025 | +1.4% | $190.90 | $190.85 | -0.03% |
| ▲ Q3 FY2025 | Jul 16, 2025 | +3.4% | $155.17 | $164.78 | +6.19% |
| ▲ Q2 FY2025 | Apr 15, 2025 | +7.4% | $154.36 | $153.62 | -0.48% |
| ▲ Q1 FY2025 | Jan 22, 2025 | +2.5% | $148.15 | $145.27 | -1.94% |
| ▲ Q4 FY2024 | Oct 15, 2024 | +9.5% | $161.60 | $164.10 | +1.55% |
| ▲ Q3 FY2024 | Jul 17, 2024 | +4.1% | $151.01 | $156.58 | +3.69% |
Q2 FY2026+0.90%
Report Date
Apr 14, 2026
EPS Beat/Miss
+0.8%
Price Before
$237.96
Price After
$240.10
Q1 FY2026-0.09%
Report Date
Jan 21, 2026
EPS Beat/Miss
+0.0%
Price Before
$218.21
Price After
$218.01
Q4 FY2025-0.03%
Report Date
Oct 14, 2025
EPS Beat/Miss
+1.4%
Price Before
$190.90
Price After
$190.85
Q3 FY2025+6.19%
Report Date
Jul 16, 2025
EPS Beat/Miss
+3.4%
Price Before
$155.17
Price After
$164.78
Q2 FY2025-0.48%
Report Date
Apr 15, 2025
EPS Beat/Miss
+7.4%
Price Before
$154.36
Price After
$153.62
Q1 FY2025-1.94%
Report Date
Jan 22, 2025
EPS Beat/Miss
+2.5%
Price Before
$148.15
Price After
$145.27
Q4 FY2024+1.55%
Report Date
Oct 15, 2024
EPS Beat/Miss
+9.5%
Price Before
$161.60
Price After
$164.10
Q3 FY2024+3.69%
Report Date
Jul 17, 2024
EPS Beat/Miss
+4.1%
Price Before
$151.01
Price After
$156.58
Avg Beat Reaction+1.22%
Beat Rate8 / 8 quarters
Largest Move+6.19% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: JNJ ends December
Johnson & Johnson (JNJ) most recently reported earnings on April 14, 2026 for Q2 FY2026, posting EPS of $2.70 (in line with the analyst consensus of $2.68). JNJ has beaten EPS estimates for 11 consecutive quarters. The next JNJ earnings date is expected around September 1, 2026.
Each quarter, investors track JNJ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. JNJ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
JNJ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
JNJ earnings · 4 questionsJohnson & Johnson's next earnings report is expected around September 1, 2026. JNJ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; JNJ historically reports after market close (AMC).
JNJ earnings datewhen is JNJ earningsJNJ next earnings datewhen does JNJ report earningsJNJ earnings calendar
▸ Source: FMP · Johnson & Johnson SEC filings · US GAAP · Johnson & Johnson SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026